We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

84 hedge funds and large institutions have $382M invested in UroGen Pharma in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 17

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

53% more capital invested

Capital invested by funds: $250M → $382M (+$132M)

6% more funds holding

Funds holding: 79 → 84 (+5)

0.61% more ownership

Funds ownership: 66.27% → 66.88% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

21% less call options, than puts

Call options by funds: $5.93M | Put options by funds: $7.48M

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
13
Increased
39
Reduced
17
Closed
8
Calls
$5.93M
Puts
$7.48M
Net Calls
-$1.55M
Net Calls Change
-$2.89M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$22.1M
2
CS
Credit Suisse
Switzerland
+$5.97M
3
HCM
Horton Capital Management
Pennsylvania
+$3.22M
4
Millennium Management
Millennium Management
New York
+$2.6M
5
VOYA Investment Management
VOYA Investment Management
Georgia
+$2.48M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$12M
2
HCM
Highline Capital Management
New York
-$3.97M
3
PC
Pier Capital
Connecticut
-$2.68M
4
PM
Prosight Management
Texas
-$2.61M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
76
Daiwa Securities Group
Japan
$32K – – –
Macquarie Group
77
Macquarie Group
Australia
$29K +$27.4K +1,122 New
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
$27.9K -$123K -5,031 -83%
PA
79
Parallel Advisors
California
$27K +$25.6K +1,047 New
First Manhattan
80
First Manhattan
New York
$26K – – –
LC
81
Lindbrook Capital
California
$13K +$7.11K +291 +146%
US Bancorp
82
US Bancorp
Minnesota
$9K +$1.17K +48 +17%
SPIA
83
Steward Partners Investment Advisory
New York
$3K – – –
S
84
SignatureFD
Georgia
$1K -$1.98K -81 -63%
BBA
85
Baker Bros. Advisors
New York
– -$12M -672,912 Closed
HCM
86
Highline Capital Management
New York
– -$3.97M -222,776 Closed
PC
87
Pier Capital
Connecticut
– -$2.68M -150,184 Closed
PM
88
Prosight Management
Texas
– -$2.61M -146,179 Closed
Victory Capital Management
89
Victory Capital Management
Texas
– -$1.09M -61,050 Closed
AA
90
ALPS Advisors
Colorado
– -$680K -38,139 Closed
PC
91
PA Capital
Virginia
– -$192K -10,771 Closed
DCM
92
DAFNA Capital Management
California
– -$42K -2,369 Closed
1 2 3
4

URGN Hedge Fund Activity: Q2 2020 in Review

84 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2020, worth a combined $382M — up 53% from $250M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new URGN positions and 8 closed out — a net gain of 5 holders — while 39 added to existing stakes and 17 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $22.1M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $12M sold.

  • 84 institutional investors held UroGen Pharma (URGN) as of Q2 2020, up from 79 in Q1 2020.
  • Funds reported $382M of UroGen Pharma stock for Q2 2020, up 53% quarter-over-quarter.
  • 13 funds opened new UroGen Pharma positions in Q2 2020 and 8 closed out, a net change of +5 holders.
  • The largest UroGen Pharma buyer in Q2 2020 was Wellington Management Group, an estimated $22.1M added.
  • The largest UroGen Pharma seller in Q2 2020 was Baker Bros. Advisors, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2020.